2018
- January 2018 – Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer
2017
- September 2017 – Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
- May 2017 – Medicare Coverage of Prolaris® Test Expands with the Addition of Men Diagnosed with Favorable Intermediate Risk Prostate Cancer
- May 2017 – Myriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
- May 2017 – Myriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
- February 2017 – Myriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prostate Cancer
2016
- May 2016 – Myriad to Present Three New Studies at the AUA Annual Meeting
- January 2016 – Myriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium
2015
- October 2015 – Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris(R) for Members With Localized Prostate Cancer
- May 2015 – Myriad Validates Active Surveillance Threshold With Prolaris(R) for Men With Prostate Cancer
- May 2015 – Myriad to Present New Clinical Data on Prolaris(R) at the AUA 2015 Annual Meeting
- March 2015 – Myriad Announces Prolaris® Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting
2014
- October 2014 – Myriad Announces Inclusion of Prolaris® Test in NCCN Guidelines
- October 2014 – Myriad Receives Draft Medicare Coverage for Prolaris®
- February 2014 – Myriad Genetics Publishes Prolaris® Data in the Journal of Urology
- January 29, 2014 – Myriad’s Prolaris Test Significantly Modifies Treatment Decisions for Patients With Prostate Cancer
- January 23, 2014 – Myriad Genetics to Present Five Clinical Studies at 2014 ASCO GU Cancer Symposium
2013
- December 2013 – Myriad’s Prolaris® Test Guides Treatment Decisions for Men with Prostate Cancer
- May 2013 – Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting: Prolaris® Signature Predicts Recurrence and Mortality
- March 2013 – Myriad’s Prolaris Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
2012
- November 2012 – Myriad Genetics’ Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy
- February 27, 2012 – Prolaris Test Awarded Best Poster Honor at 27th Annual EAU Congress in Paris, France
- February 2, 2012 – Myriad’s Prolaris Test Shown to Significantly Predict Biochemical Recurrence Risk After Prostatectomy
2011
- June 2011 – Myriad’s Prolaris Test Shown to Significantly Predict Prostate Cancer Outcome From Needle Biopsy Tissue
- May 2011 – Myriad Genetics Announces Presentation of Prostate Cancer Study at American Society for Clinical Oncology Annual Meeting
- March 2011 – Myriad Genetics Launches Prolaris: First Diagnostic Test to Predict Prostate Cancer Recurrence
- February 2011 – Myriad’s Prolaris Test Shown to Significantly Predict Prostate Cancer Outcome
2010
- October 14, 2010 – Myriad Genetics to Present Prostate Cancer Data at the ASCO-NCI-EORTC Annual Meeting on Molecular Markers in Cancer
- October 11, 2010 – Myriad Genetics’ Prolaris Test Accurately Predicts Survival with Prostate Cancer
- March 2010 – Novel Gene Expression Test, Prolaris, Accurately Predicts Prostate Cancer Recurrence